Oric Pharmaceuticals, Inc.

As of October 24, 2025, Oric Pharmaceuticals, Inc. has a bullish technical trend supported by positive MACD and Bollinger Bands, despite some mildly bearish signals from KST and OBV, and it has significantly outperformed the S&P 500 with a year-to-date return of 62.33%.

As of October 24, 2025, Oric Pharmaceuticals, Inc. has a bullish technical trend, supported by strong MACD and Bollinger Band indicators, despite some mildly bearish signals in KST and OBV, and it has significantly outperformed the S&P 500 year-to-date with a return of 62.33%.

As of August 6, 2025, Oric Pharmaceuticals, Inc. has a mildly bullish trend, supported by a bullish MACD and Bollinger Bands, though caution is advised due to mild bearish signals from KST and OBV, while the stock has outperformed the S&P 500 recently.

As of June 18, 2025, the market trend is neutral with mixed signals: the weekly MACD is bullish, the monthly MACD is bearish, and while Bollinger Bands suggest potential upward movement, daily moving averages are mildly bearish, indicating limited short-term gains.

As of March 2022, the management team of Oric Pharmaceuticals, Inc. includes Dr. Richard Heyman (Independent Chairman), Dr. Jacob Chacko (CEO and Director), Dr. Lori Kunkel (Director), and Mr. Peter Svennilson (Board member).

Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on overcoming cancer resistance, with a market cap of approximately $769.57 million and a recent net profit of -$30 million. The company does not currently pay dividends and has a negative return on equity of -60.46%.

As of Jun 18, Oric Pharmaceuticals, Inc. has a market capitalization of 769.57 million and reported net sales of 0.00 million with a net profit of -132.86 million over the latest four quarters. The balance sheet as of Dec'24 shows shareholder's funds of 243.12 million and total assets of 276.73 million.